A citation-based method for searching scientific literature

Wietske I Luining, Matthijs C F Cysouw, Dennie Meijer, N Harry Hendrikse, Ronald Boellaard, André N Vis, Daniela E Oprea-Lager. Cancers (Basel) 2022
Times Cited: 4







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor, Johann de Bono, Kim N Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T Tagawa, Luke T Nordquist, Nitin Vaishampayan, Ghassan El-Haddad,[...]. N Engl J Med 2021
352
50

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer.
Michael Sun, Muhammad O Niaz, Adlai Nelson, Myrto Skafida, Muhammad J Niaz. Cureus 2020
16
25

Exploring and comparing adverse events between PARP inhibitors.
Christopher J LaFargue, Graziela Z Dal Molin, Anil K Sood, Robert L Coleman. Lancet Oncol 2019
160
25

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Catherine Hanna, Kathreena M Kurian, Karin Williams, Colin Watts, Alan Jackson, Ross Carruthers, Karen Strathdee, Garth Cruickshank, Laurence Dunn, Sara Erridge,[...]. Neuro Oncol 2020
51
25

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.
Carleen Cullinane, Kelly Waldeck, Laura Kirby, Buck E Rogers, Peter Eu, Richard W Tothill, Rodney J Hicks. Sci Rep 2020
34
25

Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.
Sangeeta Ray Banerjee, Vivek Kumar, Ala Lisok, Donika Plyku, Zora Nováková, Mary Brummet, Bryan Wharram, Cyril Barinka, Robert Hobbs, Martin G Pomper. J Nucl Med 2019
14
25

Structural basis for allosteric PARP-1 retention on DNA breaks.
Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A Hancock, Jamin D Steffen, Ramya Billur, Zain M Hannan, Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt,[...]. Science 2020
106
25

The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
Ciric To, Eun-Hee Kim, Darlene B Royce, Charlotte R Williams, Ryan M Collins, Renee Risingsong, Michael B Sporn, Karen T Liby. Cancer Prev Res (Phila) 2014
53
25

Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair.
Wenhao Zhang, Chen-Yi Liao, Hajar Chtatou, Luca Incrocci, Dik C van Gent, Wytske M van Weerden, Julie Nonnekens. Cancers (Basel) 2019
14
25

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Kristell L S Chatalic, Sandra Heskamp, Mark Konijnenberg, Janneke D M Molkenboer-Kuenen, Gerben M Franssen, Marian C Clahsen-van Groningen, Margret Schottelius, Hans-Jürgen Wester, Wytske M van Weerden, Otto C Boerman,[...]. Theranostics 2016
77
25

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L Giesel, Uwe Haberkorn, Alfred Morgenstern. J Nucl Med 2018
198
25

Recent advancements in PARP inhibitors-based targeted cancer therapy.
Ping Zhou, Justin Wang, Daniel Mishail, Cun-Yu Wang. Precis Clin Med 2020
22
25

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.
Zool Hilmi Awang, Markus Essler, Hojjat Ahmadzadehfar. Radiat Oncol 2018
10
25

DNA double-strand break repair in a cellular context.
A Shibata, P A Jeggo. Clin Oncol (R Coll Radiol) 2014
95
25

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma.
Paige Baldwin, Rostislav Likhotvorik, Nabeela Baig, Jodie Cropper, Ruth Carlson, Raushan Kurmasheva, Srinivas Sridhar. Front Oncol 2019
12
25

Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.
Malwina Czerwińska, Aleksander Bilewicz, Marcin Kruszewski, Aneta Wegierek-Ciuk, Anna Lankoff. Molecules 2020
29
25

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Todd A Hopkins, William B Ainsworth, Paul A Ellis, Cherrie K Donawho, Enrico L DiGiammarino, Sanjay C Panchal, Vivek C Abraham, Mikkel A Algire, Yan Shi, Amanda M Olson,[...]. Mol Cancer Res 2019
92
25

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Malcolm A Smith, C Patrick Reynolds, Min H Kang, E Anders Kolb, Richard Gorlick, Hernan Carol, Richard B Lock, Stephen T Keir, John M Maris, Catherine A Billups,[...]. Clin Cancer Res 2015
86
25

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.
Julie Nonnekens, Melissa van Kranenburg, Cecile E M T Beerens, Mustafa Suker, Michael Doukas, Casper H J van Eijck, Marion de Jong, Dik C van Gent. Theranostics 2016
73
25

In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio.
Cihan Gani, Carla Coackley, Ramya Kumareswaran, Christina Schütze, Mechthild Krause, Gaetano Zafarana, Robert G Bristow. Radiother Oncol 2015
37
25

"Luke! Luke! Don't! It's a trap!"-spotlight on bias in animal experiments in nuclear oncology.
Julie Nonnekens, Margret Schottelius. Eur J Nucl Med Mol Imaging 2020
5
25

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Cristina Müller, Christoph A Umbricht, Nadezda Gracheva, Viviane J Tschan, Giovanni Pellegrini, Peter Bernhardt, Jan Rijn Zeevaart, Ulli Köster, Roger Schibli, Nicholas P van der Meulen. Eur J Nucl Med Mol Imaging 2019
62
25

Trapping Poly(ADP-Ribose) Polymerase.
Yuqiao Shen, Mika Aoyagi-Scharber, Bing Wang. J Pharmacol Exp Ther 2015
129
25

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
456
25

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
Prakash Jagtap, Csaba Szabó. Nat Rev Drug Discov 2005
702
25

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy.
Wallace Jones, Kelly Griffiths, Pedro C Barata, Channing J Paller. Cancers (Basel) 2020
43
25

EANM position paper on the role of radiobiology in nuclear medicine.
An Aerts, Uta Eberlein, Sören Holm, Roland Hustinx, Mark Konijnenberg, Lidia Strigari, Fijs W B van Leeuwen, Gerhard Glatting, Michael Lassmann. Eur J Nucl Med Mol Imaging 2021
14
25

Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.
Nupur K Purohit, Rashmi G Shah, Samuel Adant, Michael Hoepfner, Girish M Shah, Jean-Mathieu Beauregard. Oncotarget 2018
29
25

Women in nuclear medicine.
Ozgul Ekmekcioglu, Laura Evangelista, Jolanta Kunikowska. Eur J Nucl Med Mol Imaging 2021
5
25

Women in academic rheumatology.
Ingrid E Lundberg, Seza Ozen, Ayse Gunes-Ayata, Mariana J Kaplan. Arthritis Rheum 2005
23
25

[Development of a national competency-based learning objective catalogue for undergraduate medical education in Germany].
Jörg Marienhagen, Winfried Brenner, Andreas Buck, Christiane Franzius, Lutz S Freudenberg, Martin Gotthardt, Oliver Lindner, Felix M Mottaghy, Dirk Hellwig. Nuklearmedizin 2018
3
33


Representation of Women as Authors of Rheumatology Research Articles.
Ekta Bagga, Sarah Stewart, Gregory D Gamble, Janine Hill, Andrew Grey, Nicola Dalbeth. Arthritis Rheumatol 2021
12
25

[Future Workshop 1.0 - Departure into the future or a flash in the pan?]
Ken Herrmann, Lutz S Freudenberg. Nuklearmedizin 2019
1
100

[RSO in clinical practice: Status in Germany 2020].
Lutz S Freudenberg, Rigobert Klett, Manfred Fischer, Barbara Boddenberg-Pätzold, Gregor Tönshoff, Norbert J Czech, Willm Uwe Kampen. Nuklearmedizin 2021
2
50

Diversity in Emergency Medicine: Are We Supporting a Career Interest in Emergency Medicine for Everyone?
John Burkhardt, Stephen DesJardins, Larry Gruppen. Ann Emerg Med 2019
13
25

Can someone look after my children while I write this COVID-19 paper?
Elske Quak, Gilles Girault, Charline Lasnon. Eur J Nucl Med Mol Imaging 2021
2
50

Artificial Intelligence in Nuclear Medicine.
Felix Nensa, Aydin Demircioglu, Christoph Rischpler. J Nucl Med 2019
43
25

CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target.
Shivani Malik, Jill M Westcott, Rolf A Brekken, Francis J Burrows. Cancers (Basel) 2021
2
50

Current use of PSMA-PET in prostate cancer management.
Tobias Maurer, Matthias Eiber, Markus Schwaiger, Jürgen E Gschwend. Nat Rev Urol 2016
347
25

Omics Analysis of Educated Platelets in Cancer and Benign Disease of the Pancreas.
Giulia Mantini, Laura L Meijer, Ilias Glogovitis, Sjors G J G In 't Veld, Rosita Paleckyte, Mjriam Capula, Tessa Y S Le Large, Luca Morelli, Thang V Pham, Sander R Piersma,[...]. Cancers (Basel) 2020
12
25


The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis.
Nicolas Stoup, Maxime Liberelle, Céline Schulz, Sumeyye Cavdarli, Romain Vasseur, Romain Magnez, Fatima Lahdaoui, Nicolas Skrypek, Fabien Peretti, Frédéric Frénois,[...]. Cancers (Basel) 2021
2
50

Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC).
Rosa Wijnen, Camilla Pecoraro, Daniela Carbone, Hamid Fiuji, Amir Avan, Godefridus J Peters, Elisa Giovannetti, Patrizia Diana. Cancers (Basel) 2021
8
25

Cancer statistics, 2022.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2022
25

Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance.
Kostas Palamaris, Evangelos Felekouras, Stratigoula Sakellariou. Cancers (Basel) 2021
8
25

Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake.
Aya Sugyo, Atsushi B Tsuji, Hitomi Sudo, Kanako Takano, Moriaki Kusakabe, Tatsuya Higashi. Cancers (Basel) 2020
3
33

The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach.
Lenka N C Boyd, Mahsoem Ali, Laura Kam, Jisce R Puik, Stephanie M Fraga Rodrigues, Eline S Zwart, Freek Daams, Barbara M Zonderhuis, Laura L Meijer, Tessa Y S Le Large,[...]. Cancers (Basel) 2022
3
33

SILAC-Based Quantitative Proteomic Analysis of Oxaliplatin-Resistant Pancreatic Cancer Cells.
Young Eun Kim, Eun-Kyung Kim, Min-Jeong Song, Tae-Young Kim, Ho Hee Jang, Dukjin Kang. Cancers (Basel) 2021
3
33

Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights.
Rosa Maria Iacobazzi, Ilaria Arduino, Roberta Di Fonte, Angela Assunta Lopedota, Simona Serratì, Giuseppe Racaniello, Viviana Bruno, Valentino Laquintana, Byung-Chul Lee, Nicola Silvestris,[...]. Cancers (Basel) 2021
1
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.